Key Segmentation
By Donor Type
-
Living Donor
-
Deceased Donor
By Type of Transplant
-
Non-Preemptive
-
Preemptive
By End User
-
Hospitals
-
Transplant Clinics
By Immunosuppressive Drug Class
-
Calcineurin Inhibitors
-
Antiproliferative Agents
-
mTOR Inhibitors
-
Corticosteroids
-
Others
By Organ Preservation Method
-
Static Cold Storage
-
Hypothermic Machine Perfusion
-
Normothermic Machine Perfusion
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Novartis AG, Astellas Pharma Inc., Sanofi, Pfizer Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., TransMedics Group, Inc., Terumo Corporation (OrganOx) and XVIVO Perfusion AB.
Key opportunities include xenotransplantation, machine perfusion, biomarker-based monitoring and expansion of transplant capacity in Asia Pacific and other emerging regions.
The major growth factor is the rising number of patients with end-stage renal disease, driven by diabetes, hypertension and aging populations.
By Donor Type, the Living Donor segment dominated the market in 2025 with an estimated 53.00% share, supported by better graft survival and planned procedures.
North America dominated the market with a share of 42.00% in 2025, driven by high transplant volumes, insurance coverage and advanced transplant centers.
